These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 21457676)

  • 1. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
    Agid O; Arenovich T; Sajeev G; Zipursky RB; Kapur S; Foussias G; Remington G
    J Clin Psychiatry; 2011 Nov; 72(11):1439-44. PubMed ID: 21457676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early use of clozapine for poorly responding first-episode psychosis.
    Agid O; Remington G; Kapur S; Arenovich T; Zipursky RB
    J Clin Psychopharmacol; 2007 Aug; 27(4):369-73. PubMed ID: 17632221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
    McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
    Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.
    Agid O; Schulze L; Arenovich T; Sajeev G; McDonald K; Foussias G; Fervaha G; Remington G
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1017-22. PubMed ID: 23706529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
    J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
    Bitter I; Czobor P; Dossenbach M; Volavka J
    Eur Psychiatry; 2005 Aug; 20(5-6):403-8. PubMed ID: 16084068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
    Moisan J; Grégoire JP
    Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
    Suzuki T; Uchida H; Watanabe K; Nakajima S; Nomura K; Takeuchi H; Tanabe A; Yagi G; Kashima H
    Hum Psychopharmacol; 2008 Aug; 23(6):455-63. PubMed ID: 18537222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
    Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
    J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.
    Cooper D; Moisan J; Gaudet M; Abdous B; Grégoire JP
    Can J Psychiatry; 2005 Dec; 50(14):901-8. PubMed ID: 16494259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
    Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
    J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.
    Advokat C; Dixon D; Schneider J; Comaty JE
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):487-95. PubMed ID: 15093956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
    Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
    Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
    Perkins DO; Gu H; Weiden PJ; McEvoy JP; Hamer RM; Lieberman JA;
    J Clin Psychiatry; 2008 Jan; 69(1):106-13. PubMed ID: 18312044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.